Document is current

Article History

Received: 24 August 2023

Accepted: 17 November 2023

First Online: 30 November 2023

Declarations

:

: Ethical approval was obtained from the local ethics committee of the Medical University of Vienna (vote nr. EK 1590/2020). Written informed consent to participate was obtained from all patients who were able to consent. For patients who were unable to consent and who succumbed during the course of intensive care treatment, the ethics committee waived the need for informed consent.

: Not applicable.

: H.S. has received honoraria for lectures, consultancy, and participation in advisory board meetings from Bayer Healthcare, Boehringer Ingelheim, TEM International. Haemonetics, Vifor, and CSL Behring. C.J.S. has received honoraria for lectures, consultancy, and participation in advisory board meetings from CSL Behring, Boehringer Ingelheim, Portola, Shionogi, and Octa, as well as research support from TEM Innovation. J.Gra. has received honoraria, research funding, and travel reimbursement from Alexion, Boehringer Ingelheim, CSL Behring, Johnson & Johnson, Instrumentation Laboratory, Mitsubishi Tanabe Pharma, Novo Nordisk, Octapharma, Portola, and Takeda. T.L.K. is employed at TAmiRNA GmbH. M.H. is CEO and co-founder of TAmiRNA. J.Gri. is co-founder and scientific advisor of TAmiRNA GmbH. MW received honoraria, research funding and travel reimbursement from Boehringer Ingelheim, CSL Behring and Mitsubishi Tanabe Pharma. The remaining authors do not declare any conflicts of interest.